The US Food and Drug Administration (FDA) has granted accelerated approval to neladalkib, sold as Nelkarmi, a new targeted treatment for people with ALK-positive non-small cell lung cancer (NSCLC) that has progressed after earlier ALK-targeted therapy.
The approval, reported on 17 November 2026, ten days before the target date, covers adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib, or with two or more ALK inhibitors plus platinum chemotherapy. In the ALKOVE-1 trial, 49% of patients previously treated with alectinib saw their tumours shrink, and about half of those who responded still had a response after 12 months. ALK-positive lung cancer often affects younger people who have never smoked, and resistance to existing treatments is a major challenge.

Imagine a 42-year-old architect who has never smoked. Three years ago, she was diagnosed with advanced lung cancer after a persistent cough. Tests showed an ALK gene change, and a targeted pill called alectinib controlled her cancer well, allowing her to keep working and caring for her children. Now scans show the cancer is growing again. Her lung cancer nurse explains that a new ALK medicine has just received accelerated approval in the US for people in exactly her situation. It was designed to overcome common resistance mutations and to reach the brain. She feels a mix of worry and hope as she prepares to discuss her options with her team.
What happened
The FDA granted accelerated approval to neladalkib (Nelkarmi), developed by Nuvalent, as reported on 17 November 2026. The FDA’s target action date had been 27 November.
Neladalkib is approved for adults with locally advanced or metastatic ALK-positive NSCLC previously treated with alectinib, or with two or more prior ALK tyrosine kinase inhibitors (TKIs) plus platinum chemotherapy.
Accelerated approval is based on response rates and duration of response. Continued approval may depend on confirmation of clinical benefit in further trials.
10 key facts
- The FDA granted accelerated approval to neladalkib (Nelkarmi).
- It is for previously treated ALK-positive non-small cell lung cancer.
- It is approved after alectinib or after two or more ALK inhibitors plus chemotherapy.
- In ALKOVE-1, 49% responded after alectinib.
- 32% responded after two or more ALK inhibitors and chemotherapy.
- About half of responders still responded after 12 months.
- Around 40% of patients had brain metastases at the start.
- Raised liver enzymes were the most common side effect.
- ALK-positive lung cancer often affects younger people who never smoked.
- Continued approval depends on confirmatory trials.
The numbers at a glance
- Reported approval: 17 November 2026 (target date 27 November)
- Post-alectinib group (n=67): 49% response rate
- 76% of responders responded for 6+ months; 52% for 12+ months
- 2+ ALK TKIs plus chemotherapy (n=155): 32% response rate
- 69% durable at 6 months; 51% at 12 months
- Overall pretreated population (n=253): 31% response; median PFS 5.7 months
- About 40% had brain metastases at baseline
- Dose reductions due to side effects: about 17%
What is ALK-positive lung cancer?
Non-small cell lung cancer is the most common type of lung cancer. In about 3 to 5 in 100 cases, the cancer is driven by a rearrangement of the ALK gene, which produces an abnormal protein that tells cancer cells to grow.
ALK-positive lung cancer is more common in younger adults and people who have never smoked or smoked lightly. It often spreads to the brain.
Targeted medicines called ALK inhibitors, such as crizotinib, alectinib, brigatinib and lorlatinib, can control the cancer for years. However, the cancer often develops resistance, partly through new mutations in the ALK gene, so more treatment options are needed.
Why this matters
Many people with ALK-positive lung cancer live for years with targeted treatment, but resistance is almost inevitable. After alectinib and other ALK inhibitors stop working, options have been limited.
Neladalkib was designed to work against ALK resistance mutations and to penetrate the brain, while avoiding a related target (TRK) that can cause neurological side effects with some other ALK inhibitors.
Response rates of nearly half in patients after alectinib offer meaningful hope for a group with limited choices.
What officials and experts said
The FDA ‘has granted accelerated approval to neladalkib (Nelkarmi)’ for ‘previously treated, ALK-positive, locally advanced or metastatic non-small cell lung cancer’, according to reports of the approval.
Investigators described most liver enzyme elevations as ‘asymptomatic laboratory abnormalities’ that were low grade, transient and reversible with dose adjustments.
What this means for you
- If you have ALK-positive lung cancer that has progressed, ask whether neladalkib or a clinical trial is an option.
- Ask whether new biopsies or blood tests are needed to look for resistance mutations.
- Have regular liver blood tests as advised.
- Report constipation, taste changes, swelling or cough.
- Keep attending brain scans if you have had brain metastases.
- Seek support from lung cancer nurses and patient groups.
What this means for nurses and health workers
Lung cancer nurse specialists support patients through changes in targeted therapy.
- Explain accelerated approval and what it means.
- Monitor liver tests and report changes.
- Manage constipation and taste changes.
- Monitor for swelling and breathing changes.
- Support adherence to daily oral treatment.
- Coordinate scans and follow-up.
The global picture
Lung cancer is the leading cause of cancer death worldwide. Access to molecular testing for ALK and other drivers varies widely, and many people in low- and middle-income countries are never tested. Expanding testing is key to making targeted treatments available.
Side effects
The most common side effects were raised liver enzymes (ALT in 47% and AST in 44%, with some severe), constipation (28%), taste changes (23%), swelling of the legs (18%), cough (16%) and nausea (16%). About 17% of patients needed a dose reduction, mostly because of liver enzyme changes.
Tell your team about any other medicines you take, as some may need checking for interactions.
Brain metastases
ALK-positive lung cancer often spreads to the brain. About 40% of patients in the trial had brain metastases at the start. Neladalkib was designed to reach the brain, and brain responses were measured as a secondary endpoint, though detailed results were not reported in coverage of the approval.
What is accelerated approval?
Accelerated approval allows the FDA to approve medicines for serious conditions based on early evidence, such as tumour shrinkage, that is likely to predict benefit. Further studies must confirm the benefit.
Testing for ALK
Every person with advanced non-squamous NSCLC should be tested for ALK and other drivers, using tissue or blood tests, before starting treatment.
Living with ALK-positive lung cancer
Many people continue to work and live active lives on targeted treatments. Patient organisations offer support and information.
Clinical trials
Trials of neladalkib in people who haven’t yet had ALK treatment are ongoing and may change how it is used in future.
Coping with uncertainty
Hearing that cancer has progressed can be very hard, even for people who have lived with it for years. Feelings of fear, frustration and grief are common. It can help to ask your team to explain clearly what the scans show, what options exist, and what each might mean for daily life. Some people want detailed statistics, while others prefer to focus on next steps. Lung cancer nurse specialists, counsellors and support groups can help patients and families cope, and palliative care teams can support symptom control and quality of life at any stage alongside cancer treatment.
Why new ALK medicines keep being developed
Each generation of ALK inhibitors has tried to solve a problem left by the one before. Crizotinib, the first, worked well but often failed to control cancer in the brain. Second-generation medicines such as alectinib and brigatinib improved brain control and lasted longer. Lorlatinib, a third-generation medicine, overcame many resistance mutations but can cause mood, memory and weight changes in some people. Neladalkib was designed to target ALK while sparing a related protein called TRK, which is thought to contribute to some neurological side effects, and to remain active against compound mutations, where the cancer develops more than one change in the ALK gene. Researchers hope that choosing the right medicine at the right time, guided by testing, will help people live longer with good quality of life.
Myths and facts
Myth: Only smokers get lung cancer.
Fact: ALK-positive lung cancer often affects people who never smoked.
Myth: Targeted treatments work forever.
Fact: Resistance usually develops, so new options matter.
Myth: Accelerated approval means unproven.
Fact: It is based on meaningful early evidence, with confirmation required.
Myth: Brain spread means no treatment works.
Fact: Several ALK inhibitors reach the brain.
Questions and answers
What is neladalkib?
A targeted ALK inhibitor for lung cancer.
Who is it for?
Adults with ALK-positive NSCLC previously treated with alectinib or several ALK inhibitors.
How effective is it?
49% responded after alectinib in ALKOVE-1.
What are the side effects?
Liver enzyme rises, constipation and taste changes.
Is it a pill?
Yes, it is taken by mouth.
What is accelerated approval?
Approval based on early evidence, pending confirmation.
Is it available outside the US?
That depends on decisions in other countries.
What happens next
Confirmatory trials will assess whether neladalkib improves survival, and studies in earlier lines of treatment are ongoing. Regulators in other countries may review the medicine. We will report further results.
Key takeaways
- The FDA granted accelerated approval to neladalkib (Nelkarmi).
- It is approved after alectinib or after two or more ALK inhibitors plus chemotherapy.
- 32% responded after two or more ALK inhibitors and chemotherapy.
- Around 40% of patients had brain metastases at the start.
- ALK-positive lung cancer often affects younger people who never smoked.
- Continued approval depends on confirmatory trials.
How we report health news
Nursing Media Network reports health news using official sources such as the World Health Organization, national public health agencies, medicines regulators and peer-reviewed research, which are linked at the end of each story. Figures in fast-moving stories, such as outbreaks, change quickly, so we state the date each number refers to. If you are reading this later, check the latest update from the official source before making decisions.
News reports describe what has happened across a population. They cannot tell you what is right for your own health. If a story raises questions about your treatment, symptoms or risk, speak to your nurse or healthcare provider before making any changes.
Staying informed without feeling overwhelmed
A constant stream of health headlines can leave people anxious or confused. It can help to choose one or two trusted sources and check them at set times, rather than scrolling throughout the day. Focus on what you can control, such as vaccinations, regular check-ups, healthy routines and knowing when to seek care. Talk about worries with family, friends or your nurse rather than keeping them to yourself, and take a break from news if it is affecting your sleep or mood. Being informed is useful; being overwhelmed is not.
Finding reliable health information
Health information online varies widely in quality. Prefer sources such as the World Health Organization, national health ministries, public health agencies, university hospitals and registered professional bodies. Be cautious with social media posts, miracle cures and products sold with promises that sound too good to be true.
If you read something that worries you or contradicts the advice you have been given, write it down and discuss it with your nurse or healthcare provider. They can explain how it applies to your own situation and help you separate evidence from rumour.
Questions to ask your nurse or healthcare provider
- Is neladalkib an option for me?
- Should I have a new biopsy or blood test?
- How will my liver be monitored?
- What should I do about side effects?
- Are there clinical trials I could join?
- How will my brain be monitored?
But if earlier ALK treatments stopped working, is there anything left?
Yes. Newer ALK inhibitors such as neladalkib are designed to overcome resistance, and clinical trials offer further options.
Your next step: If your ALK-positive lung cancer has progressed, ask your oncology team about newer ALK treatments and clinical trials.
Related: Stopping smoking
Sources: OncLive, 17 November 2026; FDA: novel drug approvals 2026.



Leave a Reply